trending Market Intelligence /marketintelligence/en/news-insights/trending/XSVefKvl-3JO9wXgPoM0hA2 content esgSubNav
In This List

J&J seeks EU approval of Imbruvica-Rituxan combo as initial blood cancer therapy

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


J&J seeks EU approval of Imbruvica-Rituxan combo as initial blood cancer therapy

Johnson & Johnson filed an application with the European Medicines Agency seeking approval of a combination of its drug Imbruvica and Roche Holding AG's Rituxan as a first-line treatment for a type of blood cancer.

The company's application is backed by data from a late-stage study that evaluated the combination therapy against the standard of care in 529 patients with previously untreated chronic lymphocytic leukemia.

CLL is a type of cancer that affects the white blood cells and occurs in the bone marrow.

Results from the study showed that the combination therapy proved to be better than a chemotherapy-based standard of care in extending the life-span of patients without the disease worsening.

North Chicago, Ill.-based AbbVie Inc. co-markets Imbruvica, or ibrutinib, in the U.S. with J&J's Janssen Pharmaceutical Ltd. The medication is currently approved for various blood cancer indications.